Blog
About

9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bone metastases from renal cell carcinoma (RCC) are a major cause of morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients at risk of skeletal-related events (SREs) among those receiving zoledronic acid. This study sought to evaluate the effect on bone metastases of everolimus alone compared with everolimus plus zoledronic acid.

          Related collections

          Author and article information

          Journal
          Clin Genitourin Cancer
          Clinical genitourinary cancer
          1938-0682
          1558-7673
          Feb 2015
          : 13
          : 1
          Affiliations
          [1 ] Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand. Electronic address: ReubenB@adhb.govt.nz.
          [2 ] Cancer Trials New Zealand, Discipline of Oncology, University of Auckland, New Zealand.
          [3 ] Cancer Trials New Zealand, Discipline of Oncology, University of Auckland, New Zealand; Department of Preventative and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
          [4 ] Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand.
          [5 ] Midcentral Regional Cancer Treatment Service, Palmerston North Hospital, Palmerston North, New Zealand.
          [6 ] Oncology Service, Christchurch Hospital, Christchurch, New Zealand.
          [7 ] Regional Cancer Centre, Waikato Hospital, Hamilton, New Zealand.
          [8 ] Wellington Blood and Cancer Centre, Wellington Hospital, Wellington, New Zealand.
          [9 ] Tauranga Hospital, Tauranga, New Zealand.
          [10 ] Department of Medicine, University of Auckland, Auckland, New Zealand.
          Article
          S1558-7673(14)00136-0
          10.1016/j.clgc.2014.07.002
          25163397
          Copyright © 2015 Elsevier Inc. All rights reserved.

          Comments

          Comment on this article